BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31310951)

  • 21. Risk of cardiovascular disease among Nordic childhood cancer survivors with diabetes mellitus: A report from adult life after childhood cancer in Scandinavia.
    Winther JF; Bhatia S; Cederkvist L; Gudmundsdottir T; Madanat-Harjuoja L; Tryggvadottir L; Wesenberg F; Hasle H; Sällfors Holmqvist A;
    Cancer; 2018 Nov; 124(22):4393-4400. PubMed ID: 30307617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comorbidities and cardiovascular disease risk in older breast cancer survivors.
    Haque R; Prout M; Geiger AM; Kamineni A; Thwin SS; Avila C; Silliman RA; Quinn V; Yood MU
    Am J Manag Care; 2014; 20(1):86-92. PubMed ID: 24512167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations of Health-Related Quality of Life and Sleep Disturbance With Cardiovascular Disease Risk in Postmenopausal Breast Cancer Survivors.
    Vasbinder A; Zaslavsky O; Heckbert SR; Thompson H; Cheng RK; Saquib N; Wallace R; Haque R; Paskett ED; Reding KW
    Cancer Nurs; 2023 Nov-Dec 01; 46(6):E355-E364. PubMed ID: 35816026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of cardiovascular disease with health-related quality of life among older women with early-stage breast cancer undergoing adjuvant endocrine therapy.
    Liu YS; Liu Y; Park C
    J Geriatr Oncol; 2023 Sep; 14(7):101598. PubMed ID: 37549476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Life's Simple 7 with incident cardiovascular disease in 53 974 patients with cancer.
    Kaneko H; Suzuki Y; Ueno K; Okada A; Fujiu K; Matsuoka S; Michihata N; Jo T; Takeda N; Morita H; Kamiya K; Node K; Yasunaga H; Komuro I
    Eur J Prev Cardiol; 2022 Dec; 29(18):2324-2332. PubMed ID: 36056806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proximal aortic distensibility is an independent predictor of all-cause mortality and incident CV events: the MESA study.
    Redheuil A; Wu CO; Kachenoura N; Ohyama Y; Yan RT; Bertoni AG; Hundley GW; Duprez DA; Jacobs DR; Daniels LB; Darwin C; Sibley C; Bluemke DA; Lima JAC
    J Am Coll Cardiol; 2014 Dec; 64(24):2619-2629. PubMed ID: 25524341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study.
    Florido R; Daya NR; Ndumele CE; Koton S; Russell SD; Prizment A; Blumenthal RS; Matsushita K; Mok Y; Felix AS; Coresh J; Joshu CE; Platz EA; Selvin E
    J Am Coll Cardiol; 2022 Jul; 80(1):22-32. PubMed ID: 35772913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neighborhood attributes and cardiovascular disease risk in breast cancer survivors: The Pathways Study.
    Conroy SM; Von Behren J; Kwan ML; Kushi LH; Kim MO; Iribarren C; Roh JM; Laurent CA; Thomsen C; Chu JN; Greenlee H; Gomez SL; Shariff-Marco S
    Cancer; 2023 Aug; 129(15):2395-2408. PubMed ID: 37096827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.
    Monsees GM; Malone KE; Tang MT; Newcomb PA; Li CI
    J Natl Cancer Inst; 2011 Dec; 103(23):1752-60. PubMed ID: 22021667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Personalizing cardiovascular disease prevention among breast cancer survivors.
    Singla A; Kumar G; Bardia A
    Curr Opin Cardiol; 2012 Sep; 27(5):515-24. PubMed ID: 22874128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: a retrospective cohort study.
    Hartle JE; Tang X; Kirchner HL; Bucaloiu ID; Sartorius JA; Pogrebnaya ZV; Akers GA; Carnero GE; Perkins RM
    Am J Kidney Dis; 2012 May; 59(5):636-44. PubMed ID: 22244796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonates and mortality in women with CKD and the presence or absence of cardiovascular disease.
    Perkins RM; Kirchner HL; Matsushita K; Bucaloiu ID; Norfolk E; Hartle JE
    Clin J Am Soc Nephrol; 2014 May; 9(5):874-80. PubMed ID: 24578337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic syndrome and cardiovascular disease in cancer survivors.
    Ueno K; Kaneko H; Suzuki Y; Okada A; Matsuoka S; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Kamiya K; Ako J; Node K; Yasunaga H; Komuro I
    J Cachexia Sarcopenia Muscle; 2024 Jun; 15(3):1062-1071. PubMed ID: 38515400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral bisphosphonate use and the risk of female breast, ovarian, and cervical cancer: a nationwide population-based cohort study.
    Bae YS; Chang J; Park SM
    Arch Osteoporos; 2019 Mar; 14(1):41. PubMed ID: 30888545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daytime sleepiness predicts mortality and cardiovascular disease in older adults. The Cardiovascular Health Study Research Group.
    Newman AB; Spiekerman CF; Enright P; Lefkowitz D; Manolio T; Reynolds CF; Robbins J
    J Am Geriatr Soc; 2000 Feb; 48(2):115-23. PubMed ID: 10682939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
    Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in cardiovascular disease incidence and survival in the elderly.
    Haan MN; Selby JV; Rice DP; Quesenberry CP; Schofield KA; Liu J; Fireman BH
    Ann Epidemiol; 1996 Jul; 6(4):348-56. PubMed ID: 8876846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disparities in Cardiovascular Disease Risk Among Hispanic Breast Cancer Survivors in a Population-Based Cohort.
    Hu Q; Chang CP; Rowe K; Snyder J; Deshmukh V; Newman M; Fraser A; Smith K; Gren LH; Porucznik C; Stanford JB; Gaffney D; Henry NL; Lopez I; Hashibe M
    JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33889806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The risk of developing cardiovascular disease is increased for patients with prostate cancer who are pharmaceutically treated for depression.
    Wollersheim BM; Boekhout AH; van der Poel HG; van de Poll-Franse LV; Schoormans D
    BJU Int; 2020 Mar; 125(3):433-441. PubMed ID: 31773851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.